Full Press Release Details
Inc. Reports Third Quarter 2017 Results
Mass., November 6, 2017 - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a commercial
stage medical robotics company, today reports its financial results for the three and nine months ended September 30, 2017.
and Achievements in the Third Quarter 2017 and Year To-date
third quarter of 2017 marked Myomo's first full quarter as a publicly traded company. Total revenue for the
third quarter increased 165% year over year to $489,000, compared to $184,000 for the third quarter of 2016. Third quarter
revenue increased 59% compared with the second quarter of 2017. Gross margin in the third quarter was 75%, up from 58% in the
year ago period and from 68% last quarter. For the nine months ended September 30, 2017, total revenue increased 54% to
$1,011,000, as compared to $655,000 for the nine months ended September 30, 2016. Commercial activities in the third
| Launch of MyoPro For Veterans , a strategic awareness program that broadens accessibility of MyoPro powered upper limb orthotics (arm brace) to the many veterans of the U.S. Armed Forces that could potentially benefit from the technology. | ||
| Showcased MyoPro 2 at the American Orthotics and Prosthetics Association World Congress (AOPA) in Las Vegas, NV. Over 2,500 attendees participated in the conference. Myomo featured events included clinician presentations on patient outcomes with MyoPro. | ||
| Increased MyoPro awareness to physiatrists with events held at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly in Denver, CO. Clinician reported outcomes for a spinal cord injury patient using MyoPro was featured in the poster session. | ||
| Ongoing Ottobock clinician and sales training in Germany, with first patient fitted with MyoPro. |
activities are part of the Myomo's transition from a Controlled Introduction to beginning the scaling up of commercial operations
and distribution in US and international markets. The Company expects that these programs will result in greater patient
demand from increased awareness, more referral sources from rehab hospitals, and a broader footprint of MyoPro Centers of Excellence
for product distribution.
R. Gudonis, Chairman & CEO of Myomo, commented: "We are pleased to report 165% year over year and 59% sequential revenue
growth in the third quarter of 2017. Sales and marketing programs we have established, including MyoPro Centers of Excellence,
Ottobock distribution agreement, and next generation MyoPro 2 product line, are paving way for our growth agenda. We are pleased
to report positive clinical and patient feedback, facilitating efforts to serve the large, unmet market need to restore function
in paralyzed or weakened upper limbs."
Results for the Third Quarter Ended September 30, 2017
| Three months ended | Period-to-period | Nine months ended | Period-to-period | |||||||||||||||||||||||||||||
| September 30, | change | September 30, | change | |||||||||||||||||||||||||||||
| 2017 | 2016 | $ | % | 2017 | 2016 | $ | % | |||||||||||||||||||||||||
| Revenue | $ | 488,540 | $ | 184,194 | $ | 304,346 | 165 | % | $ | 1,011,454 | $ | 655,184 | $ | 356,270 | 54 | % | ||||||||||||||||
| Cost of revenue | 124,098 | 77,082 | 47,016 | 61 | % | 301,308 | 186,334 | 114,974 | 62 | % | ||||||||||||||||||||||
| Gross margin | $ | 364,442 | $ | 107,112 | $ | 257,330 | 240 | % | $ | 710,146 | $ | 468,850 | $ | 241,296 | 51 | % | ||||||||||||||||
| Gross margin% | 75 | % | 58 | % | 17 | % | 70 | % | 72 | % | (2 | )% |
revenue was $489,000 for the quarter ended September 30, 2017; an increase of $304,000, or 165%, as compared to the three months
ended September 30, 2016. During the quarter, product revenue increased $279,000 versus the comparable period of 2016. The increase
was due primarily to product sales to our distributor Ottobock. We recognized $30,000 of grant revenue during the three months
ended September 30, 2017 as compared to $5,000 in the year ago period.
margin was 75% for the quarter ended September 30, 2017, as compared to 58% for the three months ended June 30, 2016. The
increase was due to lower inventory and warranty provisions during the quarter, as well as higher research grant revenues
which have higher gross margins.
and development expenses were $329,000, an increase of $92,000, or 39%, during the three months ended September 30, 2017, as compared
to the three months ended September 30, 2016. The increase was primarily due to additional engineering personnel costs of $72,000.
general and administrative costs of $1,470,000 increased $667,000, or 83%, during the three months ended September 30, 2017, as
compared to the three months ended September 30, 2016, primarily due to employee compensation, which includes stock-based
compensation expense, and also due to professional fees, travel expenses and an increase in clinical research to support reimbursement
efforts for our products.
and other income, net was $176,000 during the three months ended September 30, 2017, as compared with a net expense of $84,000
in the three months ended September 30, 2016. This change was due primarily to a decrease in fair value of derivative liabilities.
The decrease in interest expense, and other expense net was due to lower interest expense reflecting the conversion of our convertible
promissory notes into common stock on June 9, 2017, our IPO closing date.
Company's net loss for the quarter ended September 30, 2017 amounted to $1,259,000, compared with a net loss of $1,018,000
for the corresponding 2016 period. Net loss available to common stockholders for the quarter ended September 30, 2017 was $1,259,000
or ($0.21) per share, compared with a net loss available to common stockholders of $1,211,000, or ($1.09) per share, for the corresponding
year ago period. The increase in net loss was primarily due higher operating expenses incurred
EBITDA1 for the quarter ended September 30, 2017 was a loss of $1,490,000, compared with a loss of $887,000 for the
corresponding 2016 period. A reconciliation of GAAP to this non-GAAP financial measure has been provided in the financial statement
tables included in this press release. An explanation of this measure is also included below under the heading "Non-GAAP
Financial Measures."
on hand at September 30, 2017 was $4,958,000, compared to $797,000 at December 31, 2016. For the nine months ended
September 30, 2017, we used $4,723,000 of cash in operating activities, compared to $2,299,000 for the nine months ended
September 30, 2016. The increase in cash reflects the net proceeds from our IPO, and $2,923,000 from our concurrent private
placement, in addition to $1,770,000 of additional convertible notes issued during the year partially offset by the
$4,723,000 million of net cash used in operating activities.
Call and Webcast Information
will hold a conference call today, November 6, 2017 at 4:30 p.m. EDT. To access the conference call, please dial 1-877-270-2148
from the U.S. or 1-412-902-6510 internationally. Please instruct to be joined into Myomo's earnings conference call.
replay of the conference call will be available approximately one hour after completion of the live conference call at the Investor
Relations page. A dial-in replay of the call will be available until November 20, 2017; please dial 1-877-344-7529 from the
U.S. or 1-412-317-0088 internationally and provide the passcode of 10113931.
Inc. is a commercial stage medical device company in the medical robotics industry, specializing in myoelectric braces, or orthotics,
for people with neuromuscular disorders. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis
designed to restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury,
traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device
that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability
to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able
to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with
sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.
Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization adjusted the impact of the write-off of
unamortized debt discount associated with conversion of convertible notes into common stock and warrants, stock based-compensation
and the impact of the fair value revaluation of our derivative liabilities.
press release contains forward-looking statements regarding the Company's future business expectations, including
the scale-up of commercial operations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a
factors include, among other things:
information about these and other factors that potentially could affect our financial results is included in Myomo's filings
with the Securities and Exchange Commission, including those contained in the risk factors section of the Company's
quarterly reports on Form 10-Q filed with the Commission. The Company cautions readers not to place undue reliance on any
such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this
release of financial information are based on our beliefs, assumptions and expectations, taking into account all information
currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No
assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be
attained, or that deviations from them will not be material and adverse. The Company disclaims any obligation subsequently to
revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the
occurrence of anticipated or unanticipated events.
has provided in this release of financial information that has not been prepared in accordance with generally accepted accounting
principles in the United States, or GAAP. This information includes Adjusted EBITDA. This non-GAAP financial measure is not in
accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies.
Myomo believes that the use of this non-GAAP financial measures provides supplementary information for investors to use in evaluating
operating performance and in comparing its financial measures with other companies in Myomo's industry, many of which present
similar non-GAAP financial measures. Adjusted EBITDA is EBITDA adjusted for the impact of the write off of unamortized debt discount
associated with conversion of convertible notes into common stock and warrants, stock based-compensation and the impact of the
fair value revaluation of our derivative liabilities. Non-GAAP financial measures that Myomo uses may differ from measures that
other companies may use. This non-GAAP financial measure disclosed by Myomo is not meant to be considered superior to or a substitute
for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with, GAAP financial measures.
Investors are encouraged to review the reconciliation of this non-GAAP measure to its most directly comparable GAAP financial
measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this
STATEMENTS OF OPERATIONS
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenue | $ | 488,540 | $ | 184,194 | $ | 1,011,454 | $ | 655,184 | ||||||||
| Cost of revenue | 124,098 | 77,082 | 301,308 | 186,334 | ||||||||||||
| Gross margin | 364,442 | 107,112 | 710,146 | 468,850 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 329,357 | 237,688 | 1,394,865 | 714,333 | ||||||||||||
| Selling, general and administrative | 1,470,058 | 803,249 | 4,047,385 | 1,932,522 | ||||||||||||
| Total operating expenses | 1,799,415 | 1,040,937 | 5,442,250 | 2,646,855 | ||||||||||||
| Loss from operations | (1,434,973 | ) | (933,825 | ) | (4,732,104 | ) | (2,178,005 | ) | ||||||||
| Other expense (income) | ||||||||||||||||
| Change in fair value of derivative liabilities | (219,374 | ) | - | (64,366 | ) | - | ||||||||||
| Debt discount on convertible notes | - | - | 5,172,000 | - | ||||||||||||
| Interest and other expense, net | 43,350 | 84,439 | 357,465 | 227,719 | ||||||||||||
| Total other expense (income) | (176,024 | ) | 84,439 | 5,465,099 | 227,719 | |||||||||||
| Net loss | (1,258,949 | ) | (1,018,264 | ) | (10,197,203 | ) | (2,405,724 | ) | ||||||||
| Deemed discount - accreted preferred stock discount | - | (27,187 | ) | (274,011 | ) | (81,554 | ) | |||||||||
| Cumulative dividend to Series B-1 preferred stockholders | - | (165,472 | ) | (287,779 | ) | (492,820 | ) | |||||||||
| Net loss available to common stockholders | $ | (1,258,949 | ) | $ | (1,210,923 | ) | $ | (10,758,993 | ) | $ | (2,980,098 | ) | ||||
| Weighted average number of common shares outstanding: | ||||||||||||||||
| Basic and diluted | 6,081,195 | 1,107,564 | 3,191,144 | 1,041,550 | ||||||||||||
| Net loss per share available to common stockholders: | ||||||||||||||||
| Basic and diluted | $ | (0.21 | ) | $ | (1.09 | ) | $ | (3.37 | ) | $ | (2.86 | ) |
| September 30, 2017 | December 31, 2016 | |||||||
| (Unaudited) | (revised) | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash | $ | 4,958,088 | $ | 797,174 | ||||
| Accounts receivable, net | 225,934 | 114,506 | ||||||
| Inventories | 123,351 | 82,435 | ||||||
| Prepaid expenses and other | 465,880 | 152,337 | ||||||
| Total Current Assets | 5,773,253 | 1,146,452 | ||||||
| Restricted cash | 52,000 | 52,000 | ||||||
| Deferred offering costs | 111,719 | 438,237 | ||||||
| Equipment, net | 21,822 | 21,563 | ||||||
| Total Assets | $ | 5,958,794 | $ | 1,658,252 | ||||
| LIABILITIES, REDEEMABLE AND CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIENCY) | ||||||||
| Current liabilities: | ||||||||
| Notes payable, shareholder, current | $ | - | $ | 876,458 | ||||
| Notes payable, MLSC, current | 597,070 | 1,193,984 | ||||||
| Accounts payable and other accrued expenses | 1,130,232 | 714,010 | ||||||
| Accrued interest, current | 4,602 | 149,580 | ||||||
| Derivative liabilities | 92,359 | - | ||||||
| Deferred revenue | 68,958 | 67,263 | ||||||
| Total Current Liabilities | 1,893,221 | 3,001,295 | ||||||
| Notes payable, shareholder, net of current portion | 876,458 | - | ||||||
| Notes payable, MLSC, net of current portion | 421,838 | - | ||||||
| Convertible promissory notes, net of debt discount | - | 2,204,235 | ||||||
| Convertible promissory notes, related party | - | 1,180,000 | ||||||
| Accrued interest, net of current portion | 191,892 | 130,937 | ||||||
| Total Liabilities | 3,383,409 | 6,516,467 | ||||||
| Redeemable and Convertible Preferred Stock: | ||||||||
| Series B-1 convertible preferred | - | 8,174,693 | ||||||
| Series A-1 convertible preferred | - | 4,497,548 | ||||||
| Total Redeemable and Convertible Preferred Stock | - | 12,672,241 | ||||||
| Commitments and Contingencies | - | - | ||||||
| Stockholders' Equity (Deficiency) | ||||||||
| Common stock | 611 | 112 | ||||||
| Undesignated preferred stock | - | - | ||||||
| Additional paid-in capital | 35,653,749 | 5,351,204 | ||||||
| Accumulated deficit | (33,072,511 | ) | (22,875,308 | ) | ||||
| Treasury stock | (6,464 | ) | (6,464 | ) | ||||
| Total Stockholders' Equity (Deficiency) | 2,575,385 | (17,530,456 | ) | |||||
| Total Redeemable and Convertible Preferred Stock and Stockholders' Equity (Deficiency) | 2,575,385 | (4,858,215 | ) | |||||
| Total Liabilities, Redeemable and Convertible Preferred Stock and Stockholders' Equity (Deficiency) | $ | 5,958,794 | $ | 1,658,252 |
CONDENSED STATEMENTS OF CASH FLOWS